Mutational Status of KRAS, BRAF, NRAS and PIK3CA in Primary Clear Cell Ovarian Carcinoma

被引:0
|
作者
Zannoni, Gian Franco
Chiarello, Gaia
Petrillo, Marco
Improta, Giuseppina
Rossi, Esther D.
Fadda, Guido
Fraggetta, Filippo
机构
[1] Univ Cattolica Sacro Cuore, I-00168 Rome, Italy
[2] IRCCS CROB Hosp, Potenza, Italy
[3] Org Osped Cannizzaro, Catania, Italy
关键词
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
1267
引用
收藏
页码:316A / 317A
页数:2
相关论文
共 50 条
  • [41] The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer
    Lambrechts, D.
    De Roock, W.
    Prenen, H.
    De Schutter, J.
    Jacobs, B.
    Biesmans, B.
    Claes, B.
    De Hertogh, G.
    Van Cutsem, E.
    Tejpar, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Comparison of KRAS, NRAS and PIK3CA mutational status in Poorly Differentiated Clusters (PDC) and corresponding main tumour mass of colon cancer
    Banesi, V.
    Bonetti, L. Reggiani
    Bettelli, S.
    Maiorana, A.
    VIRCHOWS ARCHIV, 2016, 469 : S1 - S1
  • [43] Development and characterization of reference materials for EGFR, KRAS, NRAS, BRAF, PIK3CA, ALK, and MET genetic testing
    Zhang, Wenxin
    Qu, Shoufang
    Chen, Qiong
    Yang, Xuexi
    Yu, Jing
    Zeng, Shuang
    Chu, Yuxing
    Zou, Hao
    Zhang, Zhihong
    Wang, Xiaowen
    Jing, Ruilin
    Wu, Yingsong
    Liu, Zhipeng
    Xu, Ren
    Wu, Chunyan
    Huang, Chuanfeng
    Huang, Jie
    TECHNOLOGY AND HEALTH CARE, 2023, 31 (02) : 485 - 495
  • [44] Tumor Heterogeneity Revealed by KRAS, BRAF, and PIK3CA Pyrosequencing: KRAS and PIK3CA Intratumor Mutation Profile Differences and Their Therapeutic Implications
    Kosmidou, Vivian
    Oikonomou, Eftychia
    Vlassi, Margarita
    Avlonitis, Spyros
    Katseli, Anastasia
    Tsipras, Iraklis
    Mourtzoukou, Despina
    Kontogeorgos, Georgios
    Zografos, Georgios
    Pintzas, Alexander
    HUMAN MUTATION, 2014, 35 (03) : 329 - 340
  • [45] Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer
    Ma, Brigette B.
    Mo, Frankie
    Tong, Joanna H.
    Wong, Ashley
    Wong, S. C. Cesar
    Ho, Wing M.
    Wu, Cherry
    Lam, Polly W. Y.
    Chan, K. F.
    Chan, Timothy S. K.
    Tsui, Wilson M. S.
    Tsang, Alex K. H.
    Fung, Mandy N. S.
    Chan, Anthony T. C.
    To, Ka Fai
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 (02) : 160 - 169
  • [46] PIK3CA overexpression is a possible prognostic factor for favorable survival in ovarian clear cell carcinoma
    Abe, Azusa
    Minaguchi, Takeo
    Ochi, Hiroyuki
    Onuki, Mamiko
    Okada, Satoshi
    Matsumoto, Koji
    Satoh, Toyomi
    Oki, Akinori
    Yoshikawa, Hiroyuki
    HUMAN PATHOLOGY, 2013, 44 (02) : 199 - 207
  • [47] Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
    Lurkin, Irene
    Stoehr, Robert
    Hurst, Carolyn D.
    van Tilborg, Angela A. G.
    Knowles, Margaret A.
    Hartmann, Arndt
    Zwarthoff, Ellen C.
    PLOS ONE, 2010, 5 (01):
  • [48] KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients
    Abbasabadi, Zohreh Mirzapoor .
    Asl, Dariush Hamedi
    Rahmani, Babak
    Shahbadori, Rozhin
    Karami, Sara
    Peymani, Amir
    Taghizadeh, Sara
    Rad, Fatemeh Samiee
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2023, 37 (05)
  • [49] The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
    V Eklöf
    M L Wikberg
    S Edin
    A M Dahlin
    B-A Jonsson
    Å Öberg
    J Rutegård
    R Palmqvist
    British Journal of Cancer, 2013, 108 : 2153 - 2163
  • [50] Clinicopathological correlation with mutation profiling of colorectal cancer for KRAS, BRAF, NRAS and PIK3CA genes in Indian patient cohort
    Patil, H. A.
    Barrow, C.
    Kanwar, R. K.
    Kanwar, J. R.
    Kapat, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 51 - 51